cytogen造句

• Cytogen said it will begin selling ProstaScint in early 1997.
• Cytogen Corp . : http : / / www . cytogen . com
• Cytogen Corp . : http : / / www . cytogen . com
• Bruckman called on the panel to recommend FDA approval of the Cytogen product.
• Nevertheless, many companies, like Large Scale Biology, Geneva Proteomics and Cytogen, are pursuing some aspects of proteomics.
• Cytogen will exchange six-tenths of a share for each of Cellcor's 5.5 million common shares outstanding.
• Other companies, such as Cytogen and Oxford Glycosciences, are pursuing proteomics, determining which proteins are present in particular cells.
• In clinical studies, Cytogen found that ProstaScint correctly determined the presence of spreading cancer in about 57 percent of one group of patients.
• Cytogen Corp .'s ProstaScint, an imaging agent, is used by doctors to help determine if cancer has spread beyond the prostate.
• AxCell, a subsidiary of Cytogen Corp ., a Princeton biopharmaceutical company, says its information will help develop more effective medications with fewer side effects.
• And Cytogen Corp . of Princeton, N . J ., said it had mapped the interactions of one of the roughly 70 families of human proteins.
• In 2004, together with a research team at AxCell-Cytogen company, Marius Sudol reported the first comprehensive protein interaction map for a human modular domain.
• The companies with the biggest increases in short interest were Acclaim Entertainment Inc ., Sybase Inc ., Cytogen Corp ., Cidco Inc . and Buffets Inc.
• Cytogen shares jumped 5 / 8 to 5 11 / 16 in trading of 2.39 million, more than seven times the three-month daily average.
• The FDA cleared ProstaScint for use in patients newly diagnosed with prostate cancer, and in patients whose prostate cancer may have recurred after surgical removal, Cytogen said.
• In higher risk patients, the Cytogen product correctly identified the presence of prostate cancer in 81 percent of patients and the absence of it in 67 percent of patients.
• -- Cytogen Corporation ( CYTO ) was rated " strong buy " in new coverage by analyst J . Robert Paul at Roan Capital Partners L . P.
• Cytogen Corp ., Princeton, N . J ., agreed to acquire Cellor Inc . Newton, Mass ., another biotechnology company, for $ 20 million in stock.
• Cytogen Corp .'s new agent for detecting prostate cancer can help patients and doctors better cope with the disease, the company told a Food and Drug Administration advisory committee.
• Cytogen shares have nearly doubled after the successful mapping was announced Tuesday, rising from $ 2.66 to close at $ 5.13 Friday on the Nasdaq Stock Market.